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Background: Fibroblastic foci (FF) are a major histological feature of usual interstitial pneu-
monia (UIP) in idiopathic pulmonary fibrosis (IPF) and collagen vascular diseases (non-IPF).
In addition, FF are occasionally associated with smoking-related interstitial fibrosis (SRIF).
Recent studies have suggested a role for epithelial to mesenchymal transition (EMT) in pulmo-
nary fibrogenesis.
Methods: Here, we investigated whether EMT was present in patients with IPF (n Z 19), non-
IPF (n Z 17), and SRIF (n Z 16) using morphometric immunohistochemistry, electron micro-
scopy, and confocal microscopy. All patients had received lung biopsies or lobectomies for lung
cancer.
Results: IPF and non-IPF patients displayed restrictive lung function patterns, whereas those
with SRIF presented mixed patterns. Cells within FF presented high number of alpha-smooth
muscle actin (aSMA)-staining cells; however, the foci of IPF patients showed comparatively
lower number. Moreover, colocalization of thyroid transcription factor-1 (TTF1) and aSMA
within FF showed low number of staining cells for IPF and SRIF in comparison to non-IPF
(p < 0.01). Nevertheless, all groups displayed colocalization of high rate of TTF1þ-cells andepartment, Sa˜o Paulo State University, HCFMB/UNESP; Campus de Rubia˜o Junior s/n Botucatu, Sa˜o




1378 A.T. Fabro et al.low rate of aSMAþ-cells within hyperplastic epithelioid cells in FF. Also, we observed areas with
low proportion of TTF1þcells and aSMAþcells, which were present in SRIF and non-IPF more
often than IPF (p < 0.001). Electron microscopy revealed small breaks in the alveolar basal
lamina, which allowed epithelioid cells to directly contact the collagenous matrix and fibro-
blasts. Three-dimensional reconstruction revealed intense aSMA staining within some epithe-
lioid cells, suggesting that they had gained a mesenchymal phenotype.
Conclusions: These findings constitute the first report of EMT in SRIF and suggest that EMT oc-
curs more prominently in SRIF and non-IPF than IPF.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Fibroblastic foci (FF) of pulmonary fibrosis are small focal
areas of young, myxoid-appearing matrix that contain ag-
gregates of collagen-producing myofibroblasts undergoing
active proliferation [1e3]. These foci are often identified at
the transition zone between normal uninvolved lung tissue
and abnormal fibrotic regions. FF have been hypothesized
to represent local remodeling events during acute lung
injury [2,4,5] and are believed to recapitulate processes
occurring during the healing of skin wounds [6]. In partic-
ular, FF are clinically and biologically important in disease
progression, with the amount of FF observed in surgical
lung biopsies directly correlating with progressive physio-
logic deterioration and shortened survival in patients with
IPF [7,8]. However, the role of FF in SRIF and non-IPF pa-
tients is not established.
FF are a major histological feature of usual interstitial
pneumonia (UIP). Examples of causes of UIP include sys-
temic sclerosis/scleroderma (non-IPF), idiopathic pulmo-
nary fibrosis (IPF), rheumatoid arthritis, asbestosis and
chronic nitrofurantoin toxicity [9,10]. In addition, FF are
occasionally found in patients with smoking-related
interstitial fibrosis (SRIF) [11] and may play a critical
role in the development of this fibrosing lung disease.
Although FF are clinically relevant, the mechanisms
involved in their cellular origin and formation remain ill
defined.
Recent in vitro and animal studies have suggested
that epithelial to mesenchymal transition (EMT) of alve-
olar epithelial cells occurs during pulmonary fibrogenesis.
EMT is the process by which epithelial cells lose their
phenotypic characteristics and acquire features of
mesenchymal cells, such as fibroblasts and myofibroblasts.
Indeed, pulmonary fibrosis-associated EMT has been
observed with experimental models [12,13], as well as
in vitro [14,15] and human studies [16e18]. Moreover,
EMT has been identified during embryonic differentiation
[19], tumor progression [20], renal fibrosis [21], and liver
fibrosis [22]. Therefore, we hypothesized that EMT might
represent a general phenomenon occurring during pul-
monary fibrogenesis, which is not only IPF specific. Here,
we employed immunohistochemistry, electron micro-
scopy, and confocal microscopy to investigate whether
EMT was present in tissue sections from IPF, non-IPF, and
SRIF patients.Materials and methods
Characteristics of human subjects and inclusion
criteria
Between 2006 and 2011, we consecutively enrolled patients
with IPF (nZ 19), non-IPF (n Z 17), and SRIF (nZ 16) who
underwent open or thoracoscopic lung biopsy or lobectomy
for lung cancer in our hospitals. Three lung pathologists
(ATF, VLC, and HP), who were unaware of the clinical and
physiologic findings, independently reviewed the lung bi-
opsies. In cases where the classification by these patholo-
gists differed, a consensus opinion on the overall
histopathologic pattern was reached. Histologic features of
UIP were based on a previously published report [23] and the
criteria of the American Thoracic Society/European Respi-
ratory Society (ATS/ERS) classification [9]. SRIF represented
a secondary diagnosis in smoking patients with co-existing
neoplastic disease, and its histologic features were based
on a previously published report by Katzeinstein and col-
leagues [11]. Both non-IPF and IPF patients presented with
the characteristic histopathologic pattern associated with
UIP. The study protocol was approved by the Ethical Com-
mittee of Graz University, Austria (Number 24e135 ex 11/
12). Notably, patients in an accelerated phase of interstitial
pneumonia were excluded. Also, all non-IPF patients fulfilled
the histological and clinical criteria for systemic sclerosis.Immunohistochemistry
To simultaneously characterize epithelial and mesenchymal
markers we employed a double-staining immunohisto-
chemistry protocol, which utilized antibodies against thy-
roid transcription factor-1 (TTF1; mouse monoclonal,
DAKO, Clone 8G7G3/1) and alpha-smooth muscle actin
(aSMA; mouse monoclonal, DAKO Clone 1A4). Briefly, sec-
tions were deparaffinized, fixed in acetone (5 min, 22 C),
and rehydrated in phosphate-buffered saline (PBS; pH 7.4)
for 10 min. Immunohistochemistry was performed using a
horseradish peroxidase labeled streptavidin biotin kit (HRP-
LSAB, DAKO), as recommended by the manufacturer. After
incubation with blocking solution (5 min), the sections were
incubated for 30 min with one primary antibody (diluent
from DAKO), followed by sequential 15 min incubations
with biotinylated antibody (goat anti-mouse) and
UIP and SRIF display EMT in fibroblastic foci 1379peroxidase-labeled streptavidin. The slides rinsed twice
with distilled water to not mix the different antibodies. The
same process was performed with the second primary
antibody (sequential staining). Visualization was achieved
through HRP-based reactions (TTF1, brown; aSMA, red),
which were terminated by washing with distilled water. The
sections were then counterstained with Mayer’s hemalum
and mounted with Kaiser’s glycerol gelatin (Merck, Vienna,
Austria).
Histological disease status in IPF, non-IPF, and SRIF was
assigned based on the expression of markers in regions
containing hyperplastic cells within and overlying FF.
Indeed, the number of established foci present in IPF lung
tissue relates to disease severity and the rate of disease
progression [8]. A modified quantitative assessment was
performed for each individual biopsy as previously reported
by Nicholson and colleagues [8].
Quantification of FF
Lung specimens were obtained from at least two lobes, and
all available specimens were reviewed. Hematoxylin/eosin-
stained sections were viewed at a 100-fold magnification,
and the number of FF were counted. In addition, digital
images captured at 400-fold magnification were used to
examine the expression of epithelial and mesenchymal
markers in cells within and overlying FF in IPF, non-IPF, and
SRIF sections. All hyperplasic and fusiform cells were coun-
ted, and the number of cells expressing each marker was
counted. In order to assess the intraobserver variability for
this quantitative method, the same pathologist reviewed
each specimen in different days. Additionally, interobserver
variability was examined by requiring two pathologists (HP
and ERP) to independently review each specimen.
Transmission electron microscopy (TEM)
To avoid the small nests of tangentially-sectioned,
entrapped alveolar epithelium that could be observed in





Age at biopsy (years) 65  9 54.
Spirometry
FEV1 (% pred) 70.5  14.42 77.
FVC (% pred) 65  13.85 70.
FEV1/FVC (% pred) 107.96  8.70 92.
TLC (% pred) 81  11.57 77.
RV (% pred) 117.5  35.52 98.
DLCO (% pred) 66.86  21.68 56.
DLCO/AV (% pred) 77.76  37.28 55.
Data are represented as means  standard deviations. IPF/UIP Z idio
UIP Z non-idiopathic pulmonary fibrosis/usual interstitial pneumoni
capacity; TLCZ total lung capacity; RVZ residual volume; DLCOZ d
volume.microscopy. Following fixation with 3% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.3) and a 1 h treatment with
1% osmium tetroxide (in the same buffer), tissues were
processed using standard TEM methods. Thin sectioning was
performed to trim FF-containing areas for the non-IPF
samples.
Three-dimensional reconstruction analysis
Colocalization of mesenchymal (aSMA) and epithelial
(TTF1) markers was assessed via immunofluorescence and
confocal microscopy. Briefly, lung biopsies were incubated
with antibodies against TTF1 and aSMA (same monoclonal
antibodies used for immunohistochemistry) followed by
double staining with fluorescein- and rhodamine-
conjugated goat anti-mouse IgG (dilution 1:40, Santa Cruz
Biotechnology, Santa Cruz, CA). All images were obtained
using a Zeiss LSM-410 laser-scanning confocal microscope.
Serial optical sections were performed with Simple 32 C-
imaging computer software (LSM Image Browser software,
Carl Zeiss). Z-series sections were collected every 0.6 mm
with an X60 Plan Apo lens and a scan zoom of X2. The im-
ages were collected using identical photomultiplier tube
settings, and they were processed and reconstructed with
NIH Image software.
Data collection
We collected data on patient characteristics (i.e., sex, age,
and smoking history) and assessed pulmonary function at
the time of surgical lung biopsy.
Statistical analysis
Data are expressed as means (standard deviation of the
mean) with 95% confidence intervals. We performed sta-
tistical analyses of variance, which were followed by
appropriate post-hoc tests. The Bonferroni correction was




7  7.91 61.2  6.21 NS
58  20.06 73.2  9.22 NS
87  16.88 64.9  11.95 NS
75  18.55 60.22  9.39 NS
55  20.32 79.27  25.01 NS
21  61.14 111.13  50.67 NS
27  23.18 63.72  15.29 NS
66  31.62 59.11  40.41 NS
pathic pulmonary fibrosis/usual interstitial pneumonia; non-IPF/
a; FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital
iffusing capacity of the lung for carbon monoxide; VAZ alveolar
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Table 2 Summary of quantitative results.
IHC Number of FF Mean % of cells Standard error P-value
Cells within FF TTF1þ aSMAþ IPF 122 0.65 0.50 Non-IPF  IPF <0.01
Non-IPF  SRIF Z 0.01SRIF 41 3.65 1.66
Non-IPF 86 10.93 2.14
TTF1 aSMAþ IPF 122 58.60 2.67 SRIF  IPF <0.01
Non-IPF  IPF <0.01SRIF 41 83.90 1.04
Non-IPF 86 81.86 1.74
Cells overlying FF TTF1þ aSMA IPF 115 66.52 3.06 SRIF  IPF <0.01
Non-IPF  IPF <0.01SRIF 39 88.71 0.91
Non-IPF 80 85.00 1.81
TTF1 aSMAþ IPF 115 1.91 0.53 SRIF  IPF Z 0.003
SRIF 39 6.41 1.39
UIP-L 80 3.37 0.92
TTF1 aSMA IPF 115 41.56 2.80 IPF  SRIF <0.01
IPF  Non-IPF < 0.01SRIF 39 19.48 3.09
Non-IPF 80 24.25 2.90
TTF1þ aSMAþ IPF 115 1.82 0.455 SRIF  IPF Z 0.001
Non-IPF  IPF Z 0.001SRIF 39 8.46 2.53
Non-IPF 80 6.87 1.20
Data are presented as means  standard deviations of two lung specimens obtained by open surgical biopsy or lobectomy in each patient
(all microscopic fields were analyzed in each specimen). Epithelial and mesenchymal markers were detected by immunostaining (TTF1
and aSMA, respectively). All lung specimens were analyzed for number of FF by case, percentage of TTF1þ aSMAþ cells within FF,
percentage of TTF1 aSMAþ cells within FF, percentage of TTF1þaSMAþ alveolar epithelial cells overlying FF, percentage of TTF1þ
aSMA alveolar epithelial cells overlying FF, percentage of TTF1aSMA alveolar epithelial cells overlying FF, and percentage of
TTF1aSMAþ alveolar epithelial cells overlying FF. The one-way analysis of variance (ANOVA) test and the student’s t-test were used to
compare two variables between groups. A p-value < 0.05 was considered as significant.
UIP and SRIF display EMT in fibroblastic foci 1381analysis of variance (ANOVA) test and student’s t-test were
employed when comparing two variables. All analyses were
performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). A
p-value of <0.05 was considered to be significant.
Results
Clinical features
The clinical features of the patients included in this study
are presented in Table 1. 24 patients with IPF, 30 patients
with non-IPF, and 20 patients with SRIF were consecutively
included. Patients with IPF and non-IPF displayed restric-
tive lung function patterns, which were characterized by
decreased total lung capacity (81% and 79% of predicted
values for IPF and non-IPF). Also, the FEV1/FVC ratio/100
increased in IPF and non-IPF. However, the predicted values
for DLCO and DLCO/VA in IPF and non-IPF did not signifi-
cantly differ (Table 1). SRIF patients usually presented with
mixed lung function patterns (restrictive and obstructive;
due to emphysema and concomitant tumor).Figure 1 Hematoxylin and eosin staining (BeC) and dual immun
DeL) within fibroblastic foci of IPF UIP (G, J), SRIF (E, H, K), and non
aSMA as demonstrated by staining of the bronchiolar epithelium (A
the arteriole (with vascular remodeling) (G) in IPF UIP. TTF1þ aSMA
SRIF (B, E, H, K), and non-IPF UIP (I, L) (arrows), indicating that a
chymal transition. However, epithelioid cells displaying only weak
(arrowhead) (C, F). The graph shows the percentage of TTF1þ and/o
references to color in this figure legend, the reader is referred toImmunohistochemistry
In control lung samples, which were obtained from autopsy,
TTF1 expression (epithelial marker) could be visualized
within the nuclei of bronchiolar, alveolar, and hyperplastic
epithelial cells (brown staining; Fig. 1A and D). In contrast,
aSMA (mesenchymal marker) was observed in smooth
muscle cells within the walls of remodeled arteries in IPF
(Fig. 1G). Notably, we found differential number of TTF1-
and aSMA-immunostaining cells within and overlying FF in
IPF, SRIF, and non-IPF. A total of 234 FF were counted (115
in IPF, 39 in SRIF, and 80 in non-IPF).
Fusiform cells could be visualized within FF from the IPF,
SRIF, and non-IPF sections (Fig. 1J; B,E,H,K; and C,F,I,L,
respectively). Although these cells displayed low percentage
of TTF1-staining cells (<11%), the rate of TTF1-expressing
cells were found to be significantly higher in the non-IPF
samples. As expected, the proportion of aSMA-staining
cells was high in the FF resident cells; however, the IPF
group displayed overall lower rate of aSMA expression than
the others (see Table 2 for quantitative results; Fig. 1J).ohistochemical staining for aSMA (red) and TTF1 (brown) (A,
-IPF UIP (F, I, L). The internal control was positive for TTF1 and
), emphysematous alveolar septum (D), and muscular layer of
þ cells can be observed within fibroblastic foci in IPF-UIP (J),
population of epithelial cells underwent epithelial to mesen-
expression of TTF1 can also be seen within fibroblastic foci
r aSMAþ cells within fibroblastic foci. (For interpretation of the
the web version of this article.)
Figure 2 Hematoxylin and eosin staining (AeC) and dual immunohistochemical staining for aSMA (red) and TTF1 (brown) (DeL)
overlying fibroblastic foci of IPF UIP (A, D, G, J), SRIF (B, E, H, K), and non-IPF UIP (C, F, I, L). The fibroblastic foci display
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UIP and SRIF display EMT in fibroblastic foci 1383As expected, hyperplastic epithelioid cells overlying the
FF in IPF (Fig. 2A, D, G and J), SRIF (Fig. 2B, E, H and K), and
non-IPF (Fig. 2C, F, I and L) showed high rate of TTF1-
staining cells (>65%) and low percentage of aSMA-
expressing cells (<7%). However, higher rate of TTF1- and
aSMA-expressing cells was observed in the SRIF group
(p < 0.01; Table 2; Fig. 2M). Strikingly, in all of the groups,
we detected co-expression of epithelial and mesenchymal
markers by individual epithelioid cells that were localized
in FF and near septal walls. Nevertheless, this phenomenon
was more evident in cells overlying FF in SRIF compared to
IPF (p Z 0.001; Table 2; Fig. 2M).Electron microscopy
As can be seen in Fig. 3A-E, We employed electron micro-
scopy in order to confirm that co-expression of epithelial
and mesenchymal markers was not simply an artifact of
analyzing alveolar epithelium surrounded by fibroblast-rich
connective tissue. Electron micrographs of FF were per-
formed in all groups. We exemplify the findings in non-IPF
case (Fig. 3). They revealed a central region containing a
mixed population of type 2 alveolar epithelial cells (AEC2),
amorphous extracellular matrix, fibroblasts, and neutro-
phils (Fig. 3A). However, the periphery of the FF was
composed almost exclusively of AEC2, displaying prominent
lamellar bodies (LB) (Fig. 3B). Also, densely packed struc-
tures resembling smooth muscle fibers were often present
(Fig. 3C). The matrix surrounding the AEC2 contained only
sparse collagen fibrils. Furthermore, strands of moderately
electron dense materials were present close to the cells,
which followed the plasma membranes or extended out
into the matrix in an irregular fashion (Fig. 3D). Although
these strands were of similar electron density to basal
lamina, they lacked the uniform thickness of basal lamina.
Also, high magnification revealed that they were composed
of straight fibrils embedded in a finely granular material,
which commonly obscured parts of the fibrils. The surface
of the FF was only partially covered by AEC2, usually near
sites of attachment to alveolar walls. However, no basal
lamina was present beneath the epithelium, allowing the
epithelium to make direct contact with the matrix of the
FF. Notably, at the point where the FF contacted alveolar
walls, small breaks appeared in the alveolar basal lamina,
which appeared to have a sinuous or pleated contour. Basal
lamina was often absent at the surface of foci, allowing
AEC2 to rest directly on the collagenous matrix and at times
contact fibroblasts (Fig. 3E). Even in cases where foci dis-
played surface basal lamina, it was often fragmented and
convoluted, showing infoldings into the stroma. All groups
showed the same finding, however the rate was higher in
non-IPF cases.characteristic appearances (AeC) with TTF1þ epithelial cells and aS
UIP (A, D), SRIF (B, E), and Non-IPF UIP (C, F). However, some fibr
both TTF1 and aSMA in dots (arrows) (GeL), indicating that some e
TTF1þ aSMAþ epithelial cells could be observed within the fibrobla
TTF1þ and/or aSMAþ epithelial cells overlying the fibroblastic foc
legend, the reader is referred to the web version of this article.)Three-dimensional reconstruction
Immunofluorescence images obtained via confocal micro-
scopy verified the uniform distribution of greenish nuclear
TTF1 staining in control lungs in type 2 pneumocytes
(Fig. 4A) and in hyperplastic type 2 alveolar epithelial cells
(AEC2) (Fig. 4B). However, in IPF, non-IPF and SRIF lungs,
greenish nuclear TTF1 staining of hyperplastic AEC2 showed
a diffuse distribution pattern within the FF (Fig. 4C and G).
Also, reddish cytoplasmic aSMA immunoreactivity was
observed in hyperplastic AEC2 in IPF (Fig. 4C and D), non-
IPF (Fig. 4E) and SRIF (Fig. 4F and G). In contrast, aSMA
was absent from AEC2 in the control group (Fig. 4B). Using
dual immunofluorescence staining (TTF1 and aSMA), we
confirmed that metaplastic regenerated epithelial cells
residing in the FF simultaneously expressed epithelial and
mesenchymal markers (Fig. 4CeG; arrow), suggesting the
occurrence of EMT (or possibly mesenchymal to epithelial
transition [MET]) in all groups, however the rate of double
staining cells was higher in non-IPF cases.
In summary, we have observed significant co-expression
of epithelial and mesenchymal markers in FF, which is
consistent with the presence of mixed-phenotype cells
(i.e., myofibroblast and pneumocyte) and the occurrence
of EMT in SRIF and non-IPF.Discussion
We demonstrated in vivo, in situ and in human lung samples
the presence and frequency of EMT through both epithelial
and mesenchymal markers coexpression in IPF/UIP, non-
IPF/UIP and, for the first time, in SRIF, suggesting that
EMT is a general mechanism to pulmonary fibrosis and may
contribute significantly to understanding the pathogenesis
of these disorders. . Our approach was objective by use
histomorphometry as a quantitative method. FF are a major
histological feature of UIP in IPF, some collagen vascular
diseases (non-IPF), and occasional cases of SRIF. However,
the source of these myofibroblast clusters remains to be
determined. Although some evidence has suggested a
possible role for EMT as part of this process, it remains
controversial [17,24e28]. Hosper et al. have demonstrated
that collagen I is upregulated after EMT, but it is not enough
to pulmonary remodeling [29]. However, these authors
have studied cell culture that do not have the same
microenvironment and milieu of cytokines and growth
factor of human lung that promote the intense pulmonary
remodeling. Furthermore, the interaction cell to cell and
cell to matrix is very important to migration, fixation and
transition of epithelial to mesenchymal cell.
In the current study, histological analyses revealed that
epithelioid cells residing within FF in IPF were less likely toMAþ myofibroblasts (DeF), which could be observed within IPF-
oblastic foci displayed rare epithelial cells, which stained with
pithelial cells underwent epithelial to mesenchymal transition.
stic foci (arrowhead) (H). The graph shows the percentage of
i. (For interpretation of the references to color in this figure
Figure 3 Electron microscopy in fibroblastic foci in non-IPF. The central region of the foci contain entrapped alveolar epithelium
surrounded by fibroblast-rich connective tissue (A). The cells at the periphery of the fibroblastic foci were almost exclusively type 2
alveolar epithelial cells (AEC2) with prominent lamellar bodies (LB) (B). Note the densely compact areas resembling smooth muscle
(C). The matrix surrounding these cells contained only sparse collagen fibrils in an irregular fashion (D). Small breaks in the alveolar
basal lamina allowed AEC2 to rest directly on the collagenous matrix and make contact with fibroblasts (E). Fibroblast (Fib). Citrate
of lead and uranile.
1384 A.T. Fabro et al.stain with both TTF1 and aSMA than those in SRIF and non-
IPF. In addition, the number of fusiform cells within the FF
that showed myofibroblast markers was increased in SRIF
and non-IPF lungs when compared to IPF. Moreover, double
immunostaining identified a population of cells expressing
both markers (TTF1 and aSMA), which were more
frequently stained in SRIF and non-IPF compared to IPF.
Furthermore, a significantly higher amount of TTF1þ fibro-
blastic cells were found to reside within the FF of SRIF and
non-IPF lungs in comparison to IPF. Our results may indicate
that some epithelial cells overlying fibroblastic foci lose the
epithelial phenotype and gain the mesenchymal pheno-
type, contributing at least in part to pulmonary fibrosis. In
the present study, we used aSMA and TTF1 as reliable and
stable markers for pneumocyte and myofibroblastic differ-
entiation. Our findings are in agreement with Lomas et al.
[30], who detected a significant level of aSMA expression in
hyperplastic AEC2 in IPF. In addition, Willis et al. [16]
analyzed three IPF patients and found that >80% of the
lung epithelial cells presented co-expression of TTF1 and
aSMA, whereas normal lung tissue contained no cells with
both markers. In contrast, Yamada et al. [27] analyzed 15
cases of IPF and were unable to detect cells with dual
epithelial/mesenchymal phenotype, even though they
made use of various markers (ICAM-1, E-cadherin, CD44v9,
LFA, SP-A, and vimentin). However, these markers are not
specific to pneumocyte and myofibroblast differentiation.
Thus, they could not be used to appropriately address thequestion raised by these authors. Similar data were
described by Morbini et al. [31], who could not support
complete EMT, despite the use of several markers (lam5-
g2, fibronectin, vimentin, p63, and E-cadherin). Collec-
tively, these results suggest that some epithelial cells
residing in FF lose their epithelial phenotype and gain
mesenchymal features. Thus, some fibroblastic cells in FF
may originate from epithelial cells.
Mechanistically, our data suggest that EMT is key process
contributing to the pathogenesis of pulmonary fibrosis
being a possible source of myofibroblasts to FF. However,
the EMT may be a reversible process and has been called
mesenchymal to epithelial transition (MET). Consequently
our findings may not exactly differentiate the way of
transition, but show clearly the process. The bone marrow-
derived cells may be progenitors of lung alveolar epithelium
and has been suggested that EMT/MET might be driven
mainly by bone marrow-derived stem cells, which collabo-
rate with local cells to drive chronic, long-term fibrosis.
This may be the determining factor for fibrosis severity and
could explain discrepancies in the literature related to
various subsets of patients (i.e., EMT vs. no EMT in IPF)
[17,24,28].
One possible explanation that has been raised for the
differential findings related to EMT in IPF is the temporal
limitation of the EMT phenomenon (i.e., once the cells
reach the myxoid stroma they terminally differentiate into
myofibroblasts and lose their epithelial characteristics,
Figure 4 Three-dimensional image reconstruction. Dual immunofluorescence staining reveals TTF1 (green) and aSMA (red)
colocalization in FF areas of IPF, non-IPF and SRIF. The nuclear TTF1 immunoreactivity was uniform in pneumocytes of control lungs
(arrow) (A); however, the nuclear TTF1 staining of hyperplastic AEC2 led to a diffuse pattern of distribution (B); whereas no aSMA
expression was observed in the control groups (A,B). In addition, intense aSMA staining was found in hyperplastic AEC2 (CeG).
Hyperplastic AEC2 within FF showed simultaneous staining for epithelial and mesenchymal markers in IPF (C,D), non-IPF (E) and
SRIF (F,G). In particular, hyperplastic AEC2 overlying FF showed nuclear TTF1 staining and begin to express cytoplasmtic SMA (G).
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
UIP and SRIF display EMT in fibroblastic foci 1385including TTF1 expression) as well as the timing of biopsies
[27]. Another hypothesis centers on the interaction of the
immune system with the EMT process (i.e., potentiation of
EMT by inflammatory and/or immune processes). This idea
is interesting when considering the higher frequency of
lymphocyte aggregates in cases of non-IPF (data not
shown). Also, experimental studies indicate greater
severity of pulmonary fibrosis in the presence of specific
inflammatory responses [32,33]. Additionally, the large
number of macrophages in SRIF and the pro-inflammatory
activity of cigarette smoke-induced oxidative damage [34]
could participate in activating or potentiating EMT by in-
flammatory mechanisms, potentially worsening the slow
course of SRIF and cardiovascular disease-induced UIP.
We hypothesize that precursor cells from the bronchio-
loalveolar junction move into areas of exposed alveolar
septa and initiate regeneration of the epithelial defects.
Some of these cells enter the myxoid stroma (EMT),
changing their morphology into a spindle shape and upre-
gulating expression of aSMA to enhance their motility.
These cells might stimulate the activation of resting fibro-
blasts/myofibroblasts or even transform fully into myofi-
broblasts. In addition, it is possible that other stromal cells
(resident or bone marrow derived) could access the
exposed alveolar surface and undergo MET.
Our results indicate that some epithelial cells within FF
lose their epithelial phenotype and gain mesenchymal
markers. Thus, we propose that fibroblastic cells within FForiginate directly from epithelial cells. Moreover, we
observed that this EMT process was more prominent in SRIF
and non-IPF compared to IPF; however, the reason for this
observation is currently unclear. It is possible that bone
marrow-derived cells could be involved in the pathogenesis
of IPF. Analysis of TTF1 and aSMA expression represents a
reliable and robust method for identifying EMT and MET in
lung tissue.
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